CCP-07, which is being developed by Tris Pharma, is a cough-cold formulation being developed for the US prescription cough-cold market. The FDA issued complete response letter (CRL) for CCP-07, which
The trial, dubbed EXPEDITION-1, featured patients having chronic hepatitis C virus (HCV) infected patients with genotype 1, 2, 4, 5 or 6 and compensated cirrhosis (Child-Pugh A), and subjected to
Upsher-Smith’s portfolio includes around 30 pharmaceutical products, specifically intended for oral solid preparations. The acquired business will enables Sawai to develop a US business, in addition to combining R&D
Novartis has also made an undisclosed equity investment in Canada-based Parvus. Under the terms, Novartis will develop and market products made from the Navacim technology besides taking responsibility of its
Earlier, the firm also secured breakthrough therapy status for CTL019 to treat r/r B-cell acute lymphoblastic leukemia (ALL) in pediatric and young adult patients. The University of Pennsylvania
The randomized phase 2 clinical trial, dubbed PINNACLE, featured 145 patients. Tarextumab was administered in combination with etoposide plus either cisplatin or carboplatin chemotherapy in patients who were previously untreated for
According to the company, emicizumab prophylaxis demonstrated a clinically meaningful reduction in the number of bleeds over time at this interim analysis after a median of 12 weeks
The regulator stated that the NDA requires additional clinical data to determine the most appropriate doses of the once-daily oral medication. In addition, the FDA said additional data is required
The company is developing SB208 as a broad-spectrum antifungal gel to treat superficial cutaneous fungal infections of the skin and nails such as tinea pedis and onychomycosis. Onychomycosis
Research on the vaccine, which is currently in the development stage, was carried out by The University of Texas Medical Branch (UTMB) at Galveston, US and Brazil's Instituto
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.